A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
A phase 2 trial of PM8002 and Etoposide in small-cell lung cancer, run by Biotheus Inc., active and no longer recruiting.
Overview
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC is a phase 2 interventional study registered as NCT05844150 by Biotheus Inc., with 50 participants enrolled, started 2023-06-01 and due to reach its primary completion in 2024-05-10. Interventions recorded: PM8002, Platinum and Etoposide.
Setting
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of PM8002 in Combination With Etoposide and Platinum in First-line Treatment of Extensive-Stage Small Cell Lung Cancer
Phase
Phase 2
Sponsor
Biotheus Inc.
Registry
Enrolled
50
Similar pages
not linked directly; found by shared links- TrialA Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
Shares PM8002, BioNTech, Small-cell lung cancer and the tag pipeline.
- TrialPM8002 in the Treatment of Patients With Advanced Solid Tumors
- TrialA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- TrialA First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
- TrialA Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
- TrialA Study of PM8002 in Combination With Chemotherapy in Patients With NEN
- TrialPharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms
Shares Etoposide, Small-cell lung cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)